TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of General Surgery
Division of Nuclear Medicine
Digestive System Department
Division of General Internal Medicine
更新時間：2023-09-19
許駿Hsu, Chiun
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
29Publications
11
Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver Int. 2020 Oct;40(10):2535-2543. doi: 10.1111/liv.14538. Epub 2020 Jun 9. PMID: 32463975; PMCID: PMC7540301.
12
Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. Epub 2019 Dec 20. PMID: 32067677.
13
Lin ZZ, Chen BB, Hung YP, Huang PH, Shen YC, Shao YY, Hsu CH, Cheng AL, Lee RC, Chao Y, Hsu C. A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist. 2020 Sep;25(9):e1280-e1285. doi: 10.1634/theoncologist.2020-0143. Epub 2020 Apr 9. PMID: 32271494; PMCID: PMC7485356.
14
Hung YP, Shao YY, Hsu C, Hsu CH, Lee JM, Yang MH, Chao Y. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. J Formos Med Assoc. 2021 Aug;120(8):1581-1590. doi: 10.1016/j.jfma.2020.11.015. Epub 2020 Dec 15. PMID: 33334658.
15
Dong Y, Liu TH, Yau T, Hsu C. Novel systemic therapy for hepatocellular carcinoma. Hepatol Int. 2020 Sep;14(5):638-651. doi: 10.1007/s12072-020-10073-7. Epub 2020 Jul 13. PMID: 32661949.
16
Shao YY, Wang SY, Lin SM; Diagnosis Group,; Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021 Apr;120(4):1051-1060. doi: 10.1016/j.jfma.2020.10.031. Epub 2020 Nov 14. PMID: 33199101.
17
Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025. PMID: 31954494.
18
Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X. Erratum in: Lancet Oncol. 2020 Jul;21(7):e341. PMID: 32502443.
19
Lin CC, Yang TS, Yen CJ, Cheng R, Liu J, Hsu C. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist. 2020 Dec;25(12):e1921-e1929. doi: 10.1002/onco.13550. Epub 2020 Oct 31. PMID: 33017497; PMCID: PMC8108062.
20
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. Erratum in: JAMA Oncol. 2021 Jan 1;7(1):140. PMID: 33001135; PMCID: PMC7530824.
